Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.
Corrie PG, Marshall A, Nathan PD, Lorigan P, Gore M, Tahir S, Faust G, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Goodman A, Dalgleish A, Martin-Clavijo A, Westwell S, Casasola R, Chao D, Maraveyas A, Patel PM, Ottensmeier CH, Farrugia D, Humphreys A, Eccles B, Young G, Barker EO, Harman C, Weiss M, Myers KA, Chhabra A, Rodwell SH, Dunn JA, Middleton MR; AVAST-M Investigators; Nathan P, Lorigan P, Dziewulski P, Holikova S, Panwar U, Tahir S, Faust G, Thomas A, Corrie P, Sirohi B, Kelly C, Middleton M, Marples M, Danson S, Lester J, Marshall E, Ajaz M, Houston S, Board R, Eaton D, Waterston A, Nobes J, Loo S, Gray G, Stubbings H, Gore M, Harries M, Kumar S, Goodman A, Dalgleish A, Martin-Clavijo A, Marsden J, Westwell S, Casasola R, Chao D, Maraveyas A, Marshall E, Patel P, Ottensmeier C, Farrugia D, Humphreys A, Eccles B, Dega R, Herbert C, Price C, Brunt M, Scott-Brown M, Hamilton J, Hayward RL, Smyth J, Woodings P, Nayak N, Burrows L, Wolstenholme V, Wagstaff J, Nicolson M, Wilson A, Barlow C, Scrase C, Podd T, Gonzalez M, Stewart J, Highley M, Wolstenholme V, Grumett S, Goodman A, Talbot T, Nathan K, Colt… See abstract for full author list ➔ Corrie PG, et al. Among authors: board re. Ann Oncol. 2018 Aug 1;29(8):1843-1852. doi: 10.1093/annonc/mdy229. Ann Oncol. 2018. PMID: 30010756 Free PMC article. Clinical Trial.
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.
Corrie PG, Marshall A, Nathan PD, Lorigan P, Gore M, Tahir S, Faust G, Kelly CG, Marples M, Danson SJ, Marshall E, Houston SJ, Board RE, Waterston AM, Nobes JP, Harries M, Kumar S, Goodman A, Dalgleish A, Martin-Clavijo A, Westwell S, Casasola R, Chao D, Maraveyas A, Patel PM, Ottensmeier CH, Farrugia D, Humphreys A, Eccles B, Young G, Barker EO, Harman C, Weiss M, Myers KA, Chhabra A, Rodwell SH, Dunn JA, Middleton MR. Corrie PG, et al. Among authors: board re. Ann Oncol. 2019 Dec 1;30(12):2013-2014. doi: 10.1093/annonc/mdz237. Ann Oncol. 2019. PMID: 31430371 Free PMC article. No abstract available.
Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma.
Bolte LA, Lee KA, Björk JR, Leeming ER, Campmans-Kuijpers MJE, de Haan JJ, Vila AV, Maltez-Thomas A, Segata N, Board R, Harries M, Lorigan P, de Vries EGE, Nathan P, Fehrmann R, Bataille V, Spector TD, Hospers GAP, Weersma RK. Bolte LA, et al. JAMA Oncol. 2023 May 1;9(5):705-709. doi: 10.1001/jamaoncol.2022.7753. JAMA Oncol. 2023. PMID: 36795408 Free PMC article.
Total serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma.
Visconti A, Rossi N, Deriš H, Lee KA, Hanić M, Trbojević-Akmačić I, Thomas AM, Bolte LA, Björk JR, Hooiveld-Noeken JS, Board R, Harland M, Newton-Bishop J, Harries M, Sacco JJ, Lorigan P, Shaw HM, de Vries EGE, Fehrmann RSN, Weersma RK, Spector TD, Nathan P, Hospers GAP, Sasieni P, Bataille V, Lauc G, Falchi M. Visconti A, et al. BMC Cancer. 2023 Feb 18;23(1):166. doi: 10.1186/s12885-023-10511-3. BMC Cancer. 2023. PMID: 36805683 Free PMC article.
Comparison of three-weekly and six-weekly pembrolizumab United Kingdom prescribing practice for advanced and resected melanoma.
Mehta I, Dayimu A, Kumar S, Boobier C, Oladipo O, Burke D, Olson-Brown A, Yesildag P, Nobes J, Brown S, Booth C, Wheater M, Muller D, Fountain V, Ford L, Board R, McGurk L, Twelves S, Demiris N, Corrie P. Mehta I, et al. Eur J Cancer. 2023 Nov;194:113344. doi: 10.1016/j.ejca.2023.113344. Epub 2023 Sep 17. Eur J Cancer. 2023. PMID: 37804771
A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM).
Dayimu A, Gupta A, Matin RN, Nobes J, Board R, Payne M, Rao A, Fusi A, Danson S, Eccles B, Carser J, Brown CO, Steven N, Bhattacharyya M, Brown E, Gonzalez M, Highley M, Pickering L, Kumar S, Waterston A, Burghel G, Demain L, Baker E, Wulff J, Qian W, Twelves S, Middleton M, Corrie P. Dayimu A, et al. Eur J Cancer. 2024 Jan;196:113455. doi: 10.1016/j.ejca.2023.113455. Epub 2023 Nov 24. Eur J Cancer. 2024. PMID: 38029480 Free article. Clinical Trial.
Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma.
Björk JR, Bolte LA, Maltez Thomas A, Lee KA, Rossi N, Wind TT, Smit LM, Armanini F, Asnicar F, Blanco-Miguez A, Board R, Calbet-Llopart N, Derosa L, Dhomen N, Brooks K, Harland M, Harries M, Lorigan P, Manghi P, Marais R, Newton-Bishop J, Nezi L, Pinto F, Potrony M, Puig S, Serra-Bellver P, Shaw HM, Tamburini S, Valpione S, Waldron L, Zitvogel L, Zolfo M, de Vries EGE, Nathan P, Fehrmann RSN, Spector TD, Bataille V, Segata N, Hospers GAP, Weersma RK. Björk JR, et al. Nat Med. 2024 Mar;30(3):785-796. doi: 10.1038/s41591-024-02803-3. Epub 2024 Feb 16. Nat Med. 2024. PMID: 38365950 Free PMC article.
'Get Data Out' Skin: national cancer registry incidence and survival rates for all registered skin tumour groups for 2013-2019 in England.
van Bodegraven B, Vernon S, Eversfield C, Board R, Craig P, Gran S, Harwood CA, Keohane S, Levell NJ, Matin RN, Proby C, Rajan N, Rous B, Ascott A, Millington GWM, Venables ZC; British Association of Dermatologists National Disease Registration Service Steering Committee. van Bodegraven B, et al. Br J Dermatol. 2023 May 24;188(6):777-784. doi: 10.1093/bjd/ljad033. Br J Dermatol. 2023. PMID: 36814132
A Multicentre Retrospective Study of Fulvestrant Use and Efficacy in Advanced/Metastatic Breast Cancer.
Lerner A, Keshwani K, Okines A, Sanderson B, Board RE, Flynn M, Sharkey E, Konstantis A, Roylance R, Hanna D, King J, Murphy R, Rehman F, Guppy AE, Westbury C, Takeuchi E, Spurrell E, Jayaweera HK, Raja F. Lerner A, et al. Among authors: board re. Clin Oncol (R Coll Radiol). 2022 Apr;34(4):261-266. doi: 10.1016/j.clon.2021.12.012. Epub 2022 Jan 10. Clin Oncol (R Coll Radiol). 2022. PMID: 35027287
31 results